This Article Full Text Full Text (PDF) All Versions of this Article: 90/2/627    most recent Author Manuscript (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tauchmanovà, L. Articles by Selleri, C. Search for Related Content PubMed PubMed Citation Articles by Tauchmanovà, L. Articles by Selleri, C. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Stem Cells Related Collections Calcium and Bone Metabolism

Short-Term Zoledronic Acid Treatment Increases Bone Mineral Density and Marrow Clonogenic Fibroblast Progenitors after Allogeneic Stem Cell Transplantation

Department of Molecular and Clinical Endocrinology and Oncology (L.T., G.L., A.C.), Division of Hematology (P.R., B.S., B.R., C.S.), Federico II University of Naples, 80131, Naples, Italy

Address all correspondence and requests for reprints to: Carmine Selleri, M.D., Division of Hematology, Federico II University of Naples, Via S. Pansini 5, 80131, Napoli, Italy. E-mail: selleri{at}unina.it.

Although osteoporosis is a relatively common complication after allogeneic stem cell transplantation, the role of bisphosphonates in its management has not yet been completely established. Thirty-two patients who underwent allogeneic stem cell transplantation were prospectively evaluated for bone mineral density (BMD) at the lumbar spine (LS) and femoral neck (FN) after a median period of 12.2 months. Then, 15 of the patients with osteoporosis or rapidly progressing osteopenia (bone loss > 5%/yr) received three monthly doses of 4 mg zoledronic acid iv. Fifteen patients were followed up without treatment, and all 30 patients were reevaluated after 12 months for BMD and bone turnover markers. By using enriched mesenchymal stem cells in the colony-forming units fibroblast (CFU-F) assay, we evaluated the osteogenic stromal lineage. This procedure was performed in both groups of patients at study entry and after 12 months. The average BMD loss was 3.42% at LS and 3.8% at FN during a 1-yr longitudinal evaluation in 32 patients. Subsequently, BMD increased at both LS and FN (9.8 and 6.4%, respectively) in the zoledronic acid-treated cohort. Hydroxyproline excretion decreased, and serum bone-specific alkaline phosphatase increased significantly, whereas serum osteocalcin increase did not reach the limit of significance. A significant increase in CFU-F growth in vitro was induced by in vivo zoledronic acid administration. In the untreated group, no significant change was observed in bone turnover markers, LS BMD (–2.1%), FN BMD (–2.3%), and CFU-F colony number.

In conclusion, short-term zoledronic acid treatment consistently improved both LS and FN BMD in transplanted patients who were at high risk for fast and/or persistent bone loss, partly by increasing the osteogenic progenitors in the stromal cell compartment.

This article has been cited by other articles:

				L. Tauchmanova, A. Colao, G. Lombardi, B. Rotoli, and C. Selleri REVIEW: Bone Loss and Its Management in Long-Term Survivors from Allogeneic Stem Cell Transplantation J. Clin. Endocrinol. Metab., December 1, 2007; 92(12): 4536 - 4545. [Abstract] [Full Text] [PDF]

				A. P. Grigg, P. Shuttleworth, J. Reynolds, A. P. Schwarer, J. Szer, K. Bradstock, C. Hui, R. Herrmann, and P. R. Ebeling Pamidronate Reduces Bone Loss after Allogeneic Stem Cell Transplantation J. Clin. Endocrinol. Metab., October 1, 2006; 91(10): 3835 - 3843. [Abstract] [Full Text] [PDF]

				R. L. Vessella, T. A. Guise, E. S. Susman, L. J. Suva, G. A. Clines, S. L. Kominsky, K. L. Weber, J. M. Chirgwin, L. K. McCauley, and W. Kozlow Meeting Report from Skeletal Complications of Malignancy IV: A symposium jointly sponsored by The Paget Foundation for Paget's Disease of Bone and Related Disorders, the National Cancer Institute, and the University of Virginia School of Medicine * April 28-30, 2005 in Bethesda, Maryland, USA IBMS BoneKEy, March 1, 2006; 3(3): 15 - 42. [Full Text] [PDF]

				P. R. Ebeling Defective Osteoblast Function May Be Responsible for Bone Loss from the Proximal Femur Despite Pamidronate Therapy J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 4414 - 4416. [Full Text] [PDF]

				K. Kananen, L. Volin, K. Laitinen, H. Alfthan, T. Ruutu, and M. J. Valimaki Prevention of Bone Loss after Allogeneic Stem Cell Transplantation by Calcium, Vitamin D, and Sex Hormone Replacement with or without Pamidronate J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 3877 - 3885. [Abstract] [Full Text] [PDF]